Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol
; 10(12): 869-881, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-36372069
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Estado Prediabético
/
Diabetes Mellitus Tipo 2
/
Insuficiencia Cardíaca
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Lancet Diabetes Endocrinol
Año:
2022
Tipo del documento:
Article